3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Liposarcoma
2
Endometrial Neoplasms
2
Stomach Neoplasms
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Sarcoma
1
Pancreatic Neoplasms
1
Colorectal Neoplasms
1
Carcinosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Adenosarcoma of the uterus
1
Adenocarcinoma of Lung
1
Adenocarcinoma Of Esophagus
1
Interventions
tislelizumab
1
spartalizumab
1
sintilimab
1
milademetan
1
enzalutamide
1
Pemetrexed
1
Midazolam
1
Letrozole
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fulvestrant
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Fulvestrant
×
Sarcoma
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled